Most Popular Stories
- Federal bill would link Medicare hospital pay to quality
- Express Scripts clients being extorted, too
- Moody's says healthcare's vulnerable to economy's ills
- Obama healthcare plan a plus for hospitals, Moody's says
- Pay for no extra performance?
- Wiebking named new president of Provena; Acclaimed scientist preps first skin cancer vax trial;
Poll
Featured Jobs
-
Tennessee Physician Assistant
StaffPointe, LLC - west , TN -
New York Ophthalmologist
StaffPointe, LLC - Rochester, NY -
California Internal Medicine
StaffPointe, LLC - near San Diego , CA -
Florida Otolaryngologist
StaffPointe, LLC - west , FL -
Florida Dermatology
StaffPointe, LLC - northeast , FL
Events
- World Healthcare Innovation & Technology Congress WHIT v.4.0
Dec 8-10 — Washington, DC - World Health Care Congress
April 14-16, 2009 — Washington, DC
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
Lawsuit data reveals turmoil at Guidant
Last year, just as it was putting itself up for sale to J&J, device maker Guidant was the feature of a series of articles in The New York Times in which it was accused of poorly communicating about problems with its pacemakers to physicians. Eventually, several pacemakers were recalled. Note that replacing a pacemaker means expensive and painful surgery, so this was not a trivial decision.
Now the Times features some of the discoveries from one of a number of lawsuits concerning the recall, revealing that the company knowingly sold devices that were faulty and kept doctors (not to mention patients and regulators) in the dark about what the company knew and when it knew it. Guidant was eventually sold to Boston Scientific, which has inherited the aftermath of those problems, and--given its history of stent recalls-- knows something about production problems.
- read the article in The New York Times
Related Stories
- Boston Scientific announces recall, shares drop
- The FDA warns Boston Scientific
- Guidant bid deadline approaches for J&J
- Guidant to release safety data on its devices
- ALSO NOTED: Boston Scientific settles stent dispute; Guidant issues yet another recall; Texas Hospitals prepare for Rita; and m
- Lawmakers want more data on heart devices
- Researcher settles price disclosure case with Guidant
- Patients face defibrillator recalls
- FDA report pains Boston Scientific
- Guidant warning letter drafted in 2005
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





